Evidence map›Paper›PMID 15266433›Full record

SynthesisThe Cochrane database of systematic reviews2004

Aversive smoking for smoking cessation.

P Hajek, L F Stead

Abstract readSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Relapse prevention interventions for smoking cessation.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Relapse prevention interventions for smoking cessation.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Pooled it
  6. Group behaviour therapy programmes for smoking cessation.The Cochrane database of systematic reviews · 2017
    Pooled it
  7. Pooled it
  8. Pooled it
  9. [Guidelines for smoking cessation - update 2010].Wiener klinische Wochenschrift · 2011
    Guideline
  10. Interventions for promoting smoking cessation during pregnancy.The Cochrane database of systematic reviews · 2009
    Pooled it
  11. Review
  12. Review
  13. Article
  14. Article
  15. When should meta-analysis avoid making hidden normality assumptions?Biometrical journal. Biometrische Zeitschrift · 2018
    Review
  16. Article
  17. Clinical Effects of Cigarette Smoking: Epidemiologic Impact and Review of Pharmacotherapy Options.International journal of environmental research and public health · 2017
    Review
  18. Review
  19. Rapid smoking may not be aversive in schizophrenia.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

P HajekDepartment of Human Science and Medical Ethics, St Bartholomew's and the Royal London School of Medicine and Dentistry, Turner Street, London, UK, E1 2AD.
L F Stead

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAversion therapy pairs the pleasurable stimulus of smoking a cigarette with some unpleasant stimulus. The objective is to extinguish the urge to smoke.

objectivesThis review has two aims: First, to determine the efficacy of rapid smoking and other aversive methods in helping smokers to stop smoking; Second, to determine whether there is a dose-response effect on smoking cessation at different levels of aversive stimulation. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register for studies which evaluated any technique of aversive smoking. SELECTION CRITERIA: Randomized trials which compared aversion treatments with 'inactive' procedures or which compared aversion treatments of different intensity for smoking cessation. Trials must have reported follow up of least six months from beginning of treatment. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the study population, the type of aversion treatment, the outcome measure, method of randomization and completeness of follow up. The outcome measure was abstinence from smoking at maximum follow up, using the strictest measure reported by the authors. Subjects lost to follow up were regarded as smokers. Where appropriate, we performed meta-analysis using a fixed effect model. MAIN

resultsTwenty-five trials met the inclusion criteria. Twelve included rapid smoking and nine used other aversion methods. Ten trials included two or more conditions allowing assessment of a dose-response to aversive stimulation. The odds ratio (OR) for abstinence following rapid smoking compared to control was 1.98 (95% confidence intervals (CI): 1.36 to 2.90). Several factors suggest that this finding should be interpreted cautiously. A funnel plot of included studies was asymmetric, due to the relative absence of small studies with negative results. Most trials had a number of serious methodological problems likely to lead to spurious positive results. The only trial using biochemical validation of all self reported cessation gave a non-significant result. Other aversion methods were not shown to be effective (odds ratio 1.15, 95% confidence interval 0.73 to 1.82). There was a borderline dose-response to the level of aversive stimulation (OR 1.66, 95% CI: 1.00 to 2.78). REVIEWERS'

conclusionsThe existing studies provide insufficient evidence to determine the efficacy of rapid smoking, or whether there is a dose-response to aversive stimulation. Milder versions of aversive smoking seem to lack specific efficacy. Rapid smoking is an unproven method with sufficient indications of promise to warrant evaluation using modern rigorous methodology.

Indexed as

Smoking PreventionAversive TherapyHumansSmokingSmoking Cessation

Identifiers

PMID15266433
PMCPMC7045729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.